Juvena Therapeutics
Redwood City, US · Founded 2017 · Delaware corporation · 42 employees on LinkedIn · 10 known investors
Juvena Therapeutics develops biologics derived from human secreted proteins to treat aging-related diseases, using AI-enabled drug discovery to identify tissue-restorative therapeutics for muscle and metabolic disorders.
Founders & leadership
Juvena Therapeutics was founded in 2017 by Jeremy O'Connell, PhD, Hanadie Yousef, PhD, Hanadie Yousef, Jeremy O'Connell, and Dr. Hanadie Yousef.
JO
Jeremy O'Connell, PhDChief Scientific Officer and Co-Founder
HY
Hanadie Yousef, PhDExecutive Advisor and Co-Founder
HY
Hanadie YousefCo-founder
JO
Jeremy O'ConnellCo-founder
DH
Dr. Hanadie YousefinFounder, Board Director and Executive AdvisorDr. Hanadie Yousef founded Juvena Therapeutics in 2017, serving as CEO, CFO, and Board Chair through 2025 before continuing as Board Director and Executive Advisor; the company develops biologics from human secreted proteins to treat aging-related muscle and metabolic disorders. She holds a B.S. from Carnegie Mellon and a PhD from UC Berkeley, completed postdoctoral training at Stanford School of Medicine, and also runs the advisory firm Luminous BioStrategies.
Board
Investors · 10
Bascom VenturesBoston
Bison VenturesSeattle
CompoundNew York · $400K – $1.5M
Harmonix FundLa Quinta
Horizons VenturesHong Kong · $1M – $110M
Manta Ray VenturesLondon
Open Field CapitalNew York
Plum Alley InvestmentsNew York · $500K – $1.5M
Transform Capital ManagementSan Francisco
BoxOne VenturesreportedMontréal · $500K
Reported raises · per SEC filings
Form D private placements$34.8M disclosed across 2 rounds · 2018–2025
▶$30.5MraisedJul 2025 · 12 investors · Other TechnologyRule 506(b)
▶$30.5MraisedJul 2025 · 12 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Steven JamesDirector
- Ben HemaniDirector
- Stephen JuelsgaardDirector
- Hanadie YousefExecutive Officer, Director
- Laura Lande-DinerDirector
- Christopher KirkDirector
- Ayman AlAbdallahDirector
- Jeremy O'ConnellDirector
- Offering amount
- $41M
- Amount sold
- $30.5M
- First sale
- Jun 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.3MraisedFeb 2018 · 23 investors · Other TechnologyRule 506(b)
▶$4.3MraisedFeb 2018 · 23 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Hanadie YousefExecutive Officer, Director
- Offering amount
- $4.3M
- Amount sold
- $4.3M
- First sale
- Feb 2018
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlap
IQVIA20 shared keywordsIQVIA provides data, analytics, AI, and technology-driven services for life sciences and healthcare organizations, spanning clinical development, real world evidence generation, and commercial execution. It offers integrated solutions for clinical trials, regulatory and safety compliance, and market analytics, including agentic AI products for commercial and R&D teams.
Bioworld19 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies competing with Juvena Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2021 | $254.3K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Regenerative Medicine Startup Funding (2026) – New Market Pitchnewmarketpitch.com · Jul 2026Frequently asked questions
- What does Juvena Therapeutics do?
- Juvena Therapeutics develops biologics derived from human secreted proteins to treat aging-related diseases, using AI-enabled drug discovery to identify tissue-restorative therapeutics for muscle and metabolic disorders.
- Who founded Juvena Therapeutics?
- Juvena Therapeutics was founded by Jeremy O'Connell, PhD, Hanadie Yousef, PhD, Hanadie Yousef, Jeremy O'Connell, Dr. Hanadie Yousef in 2017.
- Who are Juvena Therapeutics's investors?
- Juvena Therapeutics's investors include Bascom Ventures, Bison Ventures, Compound, Harmonix Fund, Horizons Ventures, Manta Ray Ventures, Open Field Capital, Plum Alley Investments and 2 more.
- How much funding has Juvena Therapeutics raised?
- Juvena Therapeutics has disclosed $34.8M raised across 2 rounds.
- Where is Juvena Therapeutics headquartered?
- Juvena Therapeutics is headquartered in Redwood City, US.